{"id":46776,"date":"2022-08-01T12:01:56","date_gmt":"2022-08-01T10:01:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/"},"modified":"2022-08-01T12:01:56","modified_gmt":"2022-08-01T10:01:56","slug":"selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/","title":{"rendered":"Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5321320\/selective-estrogen-receptor-degraders-pipeline?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=6dqk2j&amp;utm_campaign=1732927+-+Selective+Estrogen+Receptor+Degraders+Drug+Pipeline+Research+Report+2022&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Selective estrogen receptor degraders &#8211; Pipeline Insight, 2022&#8221;<\/a> clinical trials has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220801005366\/en\/1530293\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220801005366\/en\/1530293\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis &#8220;Selective Estrogen Receptor Degraders &#8211; Pipeline Insight, 2022&#8221; report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in the Selective Estrogen Receptor Degraders pipeline landscape.\n<\/p>\n<p>\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n<p>\n<strong>Selective Estrogen Receptor Degraders Emerging Drugs Chapters<\/strong>\n<\/p>\n<p>\nThis segment of the Selective Estrogen Receptor Degraders report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\n<\/p>\n<p>\n<strong>Selective Estrogen Receptor Degraders Emerging Drugs<\/strong>\n<\/p>\n<p>\nElacestrant: Radius Health\n<\/p>\n<p>\nElacestrant is a selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once daily oral treatment in patients with ER+\/ HER2- advanced breast cancer. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+\/HER2- advanced\/metastatic breast cancer patients.\n<\/p>\n<p>\nGiredestrant: Genentech\n<\/p>\n<p>\nGiredestrant (formerly GDC 9545) is an oral selective estrogen receptor degrader, being developed Genentech, for the treatment of breast cancer. The drug is currently in phase 3 of clinical development.\n<\/p>\n<p>\n<strong>Selective Estrogen Receptor Degraders: Therapeutic Assessment<\/strong>\n<\/p>\n<p>\nThis segment of the report provides insights about the different Selective Estrogen Receptor Degraders drugs segregated based on following parameters that define the scope of the report.\n<\/p>\n<p>\n<strong>Major Players working on Selective Estrogen Receptor Degraders<\/strong>\n<\/p>\n<p>\nThere are approx. 14+ key companies which are developing the Selective Estrogen Receptor Degraders. The companies which have their Selective Estrogen Receptor Degraders drug candidates in the most advanced stage, i.e. phase III include, Radius Health.\n<\/p>\n<p>\n<strong>Phases<\/strong>\n<\/p>\n<p>\n<strong>This report covers around 14+ products under different phases of clinical development like<\/strong>\n<\/p>\n<ul>\n<li>\nLate-stage products (Phase III and\n<\/li>\n<li>\nMid-stage products (Phase II and\n<\/li>\n<li>\nEarly-stage products (Phase I\/II and Phase I) along with the details of\n<\/li>\n<li>\nPre-clinical and Discovery stage candidates\n<\/li>\n<li>\nDiscontinued &amp; Inactive candidates\n<\/li>\n<li>\nRoute of Administration\n<\/li>\n<\/ul>\n<p>\n<strong>The Selective Estrogen Receptor Degraders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.<\/strong>\n<\/p>\n<p>\n<strong>Products have been categorized under various ROAs such as<\/strong>\n<\/p>\n<ul>\n<li>\nInfusion\n<\/li>\n<li>\nIntradermal\n<\/li>\n<li>\nIntramuscular\n<\/li>\n<li>\nIntranasal\n<\/li>\n<li>\nIntravaginal\n<\/li>\n<li>\nOral\n<\/li>\n<li>\nParenteral\n<\/li>\n<li>\nSubcutaneous\n<\/li>\n<li>\nTopical\n<\/li>\n<li>\nMolecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>Products have been categorized under various Molecule types such as<\/strong>\n<\/p>\n<ul>\n<li>\nVaccines\n<\/li>\n<li>\nMonoclonal Antibody\n<\/li>\n<li>\nPeptides\n<\/li>\n<li>\nPolymer\n<\/li>\n<li>\nSmall molecule\n<\/li>\n<li>\nProduct Type\n<\/li>\n<\/ul>\n<p>\nThe drugs have been categorized under various product types like Mono, Combination and Mono\/Combination.\n<\/p>\n<p>\n<strong>Selective Estrogen Receptor Degraders: Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Selective Estrogen Receptor Degraders therapeutic drugs key players involved in developing key drugs.\n<\/p>\n<p>\n<strong>Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Selective Estrogen Receptor Degraders drugs.\n<\/p>\n<p>\n<strong>Report Highlights<\/strong>\n<\/p>\n<ul>\n<li>\nThe companies and academics are working to assess challenges and seek opportunities that could influence Selective Estrogen Receptor Degraders R&amp;D. The therapies under development are focused on novel approaches for Selective Estrogen Receptor Degraders.\n<\/li>\n<\/ul>\n<p>\n<strong>Selective Estrogen Receptor Degraders Report Insights<\/strong>\n<\/p>\n<ul>\n<li>\nSelective Estrogen Receptor Degraders Pipeline Analysis\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<li>\nImpact of Drugs\n<\/li>\n<\/ul>\n<p>\n<strong>Selective Estrogen Receptor Degraders Report Assessment<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Product Profiles\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nPipeline Assessment\n<\/li>\n<li>\nInactive drugs assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Questions<\/strong>\n<\/p>\n<ul>\n<li>\nHow many companies are developing Selective Estrogen Receptor Degraders drugs?\n<\/li>\n<li>\nHow many Selective Estrogen Receptor Degraders drugs are developed by each company?\n<\/li>\n<li>\nHow many emerging drugs are in mid-stage, and late-stage of development for Selective Estrogen Receptor Degraders?\n<\/li>\n<li>\nWhat are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Selective Estrogen Receptor Degraders therapeutics?\n<\/li>\n<li>\nWhat are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?\n<\/li>\n<li>\nWhat are the clinical studies going on for Selective Estrogen Receptor Degraders and their status?\n<\/li>\n<li>\nWhat are the key designations that have been granted to the emerging drugs?\n<\/li>\n<\/ul>\n<p>\n<strong>Key Players<\/strong>\n<\/p>\n<ul>\n<li>\nRadius Health\n<\/li>\n<li>\nGenentech\n<\/li>\n<li>\nOlema Pharmaceuticals\n<\/li>\n<li>\nEli Lilly and Company\n<\/li>\n<li>\nAragon Pharmaceuticals\n<\/li>\n<li>\nNovartis\n<\/li>\n<li>\nSanofi\n<\/li>\n<li>\nSun Pharma Advanced Research Company\n<\/li>\n<li>\nG1 Therapeutics\n<\/li>\n<li>\nShandong Luoxin Pharmaceutical\n<\/li>\n<li>\nAstraZeneca\n<\/li>\n<li>\nZeno Alpha\n<\/li>\n<li>\nInventisBio\n<\/li>\n<li>\nAtossa Therapeutics\n<\/li>\n<li>\nEvestra\n<\/li>\n<\/ul>\n<p>\n<strong>Key Products<\/strong>\n<\/p>\n<ul>\n<li>\nElacestrant\n<\/li>\n<li>\nGiredestrant\n<\/li>\n<li>\nOP 1250\n<\/li>\n<li>\nLY 3484356\n<\/li>\n<li>\nRG 6047\n<\/li>\n<li>\nLSZ 102\n<\/li>\n<li>\nAmcenestrant\n<\/li>\n<li>\nSCO 120\n<\/li>\n<li>\nRintodestrant\n<\/li>\n<li>\nLX 039\n<\/li>\n<li>\nAZD 9833\n<\/li>\n<li>\nZN c5\n<\/li>\n<li>\nD 0502\n<\/li>\n<li>\nFulvestrant intraductal\n<\/li>\n<li>\nEC 372\n<\/li>\n<\/ul>\n<p>\nFor more information about this clinical trials report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5321320\/selective-estrogen-receptor-degraders-pipeline?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=6dqk2j&amp;utm_campaign=1732927+-+Selective+Estrogen+Receptor+Degraders+Drug+Pipeline+Research+Report+2022&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/lxj9v6<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#x3a;&#x70;r&#101;&#115;&#x73;&#x40;r&#101;&#x73;&#x65;a&#114;&#x63;&#x68;a&#110;&#100;&#x6d;&#x61;r&#107;&#x65;&#x74;s&#46;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;r&#x65;&#115;&#x73;&#x40;r&#x65;&#115;&#x65;&#x61;r&#x63;&#104;&#x61;&#x6e;d&#x6d;&#97;&#x72;&#x6b;e&#x74;&#115;&#x2e;&#x63;o&#x6d;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Selective estrogen receptor degraders &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. This &#8220;Selective Estrogen Receptor Degraders &#8211; Pipeline Insight, 2022&#8221; report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in the Selective Estrogen Receptor Degraders pipeline landscape. It covers the pipeline drug profiles, including clinical and &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46776","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Selective estrogen receptor degraders &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. This &#8220;Selective Estrogen Receptor Degraders &#8211; Pipeline Insight, 2022&#8221; report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in the Selective Estrogen Receptor Degraders pipeline landscape. It covers the pipeline drug profiles, including clinical and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-01T10:01:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220801005366\/en\/1530293\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-08-01T10:01:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/\"},\"wordCount\":835,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005366\\\/en\\\/1530293\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/\",\"name\":\"Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005366\\\/en\\\/1530293\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-08-01T10:01:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005366\\\/en\\\/1530293\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005366\\\/en\\\/1530293\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Selective estrogen receptor degraders &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. This &#8220;Selective Estrogen Receptor Degraders &#8211; Pipeline Insight, 2022&#8221; report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in the Selective Estrogen Receptor Degraders pipeline landscape. It covers the pipeline drug profiles, including clinical and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-01T10:01:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220801005366\/en\/1530293\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 &#8211; ResearchAndMarkets.com","datePublished":"2022-08-01T10:01:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/"},"wordCount":835,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220801005366\/en\/1530293\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/","name":"Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220801005366\/en\/1530293\/21\/logo.jpg","datePublished":"2022-08-01T10:01:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220801005366\/en\/1530293\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220801005366\/en\/1530293\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/selective-estrogen-receptor-degraders-drug-pipeline-research-report-2022-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Selective Estrogen Receptor Degraders Drug Pipeline Research Report 2022 &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46776"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46776\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}